[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Christian Hospital Northeast Northwest\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":47},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":5},"100631377","intrathecal-ziconotide-in-chemotherapy-induced-peripheral-neuropathy-100631377",false,"NCT07499882","Intrathecal Ziconotide in Chemotherapy Induced Peripheral Neuropathy","Observational and Data Collection Study About Intrathecal Ziconotide in the Treatment of Chemotherapy Induced Neuropathy","Inclusion Criteria:\n\n* Adult patients, ages 18-100, with chemotherapy-induced peripheral neuropathy as a primary source of pain\n* The patient is already scheduled to be treated with TDD using ziconotide (no reported allergies to ziconotide or drug-drug interactions expected)\n* Patient will have, or is scheduled to have, Medtronic Synchromed Intrathecal Pump implanted by Dr. Beuer (outside of the research)\n* Patients already taking nonopioid analgesics will be allowed to continue their prescribed medication regimen.\n* Patients currently taking opioid analgesics must undergo a washout period of 2 weeks (prior to device implant) before participating in this study. Those unable to adhere to this washout period will be excluded\n\nExclusion Criteria:\n\n* Patients with other forms of neuropathy (diabetic, idiopathic) will be excluded\n* Patients with a spinal cord stimulator will be excluded\n* Patients with contraindications to intrathecal ziconotide will be excluded\n* Patients who cannot sign the consent, participate in research activities, or those who require a legally authorized representative (LAR) will be excluded\n* Patients who are pregnant and\u002For nursing or planning to become pregnant are excluded\n* Also excluded are those inaccessible for follow-up, participation is excluded by local law, or a patient is currently enrolled or plans to enroll in a concurrent drug\u002Fdevice study","ALL","18 Years","100 Years",{"count":20,"type":21},24,"ESTIMATED","OBSERVATIONAL","The purpose of this observational, data collection, research is to evaluate if ziconotide, a commercially approved medication given by a FDA cleared intrathecal pump, for chronic pain is effective in the treatment of chemotherapy-induced peripheral neuropathy (CIPN) a common and often long-lasting side effect of cancer treatment.",[25],"Chemotherapy Induced Peripheral Neuropathy (CIPN)",[27,28,29,30,31,32,33,34],"intrathecal pump","ziconotide","chronic pain","targeted drug delivery","neuropathy","cipn","chemotherapy induced neuropathy","neuropathy after cancer treatment","NOT_YET_RECRUITING","2026-03-25",{"date":38,"type":39},"2026-03-30","ACTUAL",{"date":41,"type":21},"2026-05-02",{"date":43,"type":21},"2028-05-01",{"name":45,"class":46},"Christian Hospital Northeast Northwest","OTHER",""]